Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Therapeutics P3 Spring > Exam 5 lecture 2 (pt 1) > Flashcards

Exam 5 lecture 2 (pt 1) Flashcards

1
Q

what are some risk factors for infection in immunocompromised host

A

Neutropenia
Immune system defects
Destruction of protective barriers
environmental contamination/alternation of microbial flora

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What ANC is neutropenia?

A

less than 1000 cells

high risk<500
Higest risk<100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the two types of immune system defects

A

Defects in cell mediated immunity
Defects in humoral immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Link between duration and rapidity of decline and risk for patient

A

Increased rapidity and duration leads to increased risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Highest risk patients have neutropenia lasting how long

A

7-10 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are common bacterial pathogens seen in infections seen in immunocompromise dhosts

A

S aureus
enterobacterales
pseudomonas aeruginosa (top 3 highest fatality)

S. epidermidis
Streptococci
Enterococcus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are fungi seen in immune compromise dpatients

A

Candida
Aspergilis
Zygomycetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are viruses seen in immune compromised patients

A

HSV
VZV
CMV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are cell mediated immuntity (cells involved and intra/extracellular)

A

T lymphocytes
Primary defense against intracellular pathogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is humoral immuntity (cells involved and intra/extracellular)

A

B lymphocytes
Primary defense against extracellular pathogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

defects in T lymphocyte and macrophage function relay on 2 things

A

Underlying disease (hodgkins lymphoma)
Immunosuppressive drugs (tacrolimus and sarolimus, steroids)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Defects in B lymphocyte function and macrophage function relay on 2 things

A

Underlying disease (MM, CLL, splenectomy)

Immunosuppressive drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Common pathogens seen in skin destruction of protective barriers

A
  • Venipuncture/lines
  • Common pathogens
    -S. Aureus
    - S. Epidermis
    - Candida spp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are common pathogens seen in mucous membranes

A

chemotherapy, radiation
Common pathogens
bacteria
- s. aureus
- s epidermis
- streptococci
- enterobacterales
- P. aeruginosa
- Bacteroides spp

Fungi
- candida spp

Virus
-HSV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

compare pathogens seen in mucous membranes and surgery

A

same except no streptococci in surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what happens to oropharyngeal flora in hospitalized pts

A

They rapidly change to gram negative bacilli in hospitalized pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the number 1 cause of death in neutropenic cancer pts

A

Infection
profound neutropenia (ANC<500)= greatest risk of infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

febrile episodes are attributed to microbiologically documented infection how often

A

30-40%

(we grow something only 20-40% of the time)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what % of infections in neutropenic cancer patients are gram positive

A

45-75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are gram positive and gram negative bacterial infections seen in neutropenic cancer patients

A

Gram Positive
staph
- MSSA, MRSA

Viridians strep
- mucositis

Gram negative

Enterobacterales
- E coli, klebsiella spp

P. Aeruginosa
- high morbidity and mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What type of fungal infections do we see with neutropenic cancer patients

A
  • Candida spp (60%)
  • aspergillus spp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

WHo is at highest risk for invasive fungal infections

A

Prolonged neutropenia + broad spectrum antibiotics and/or steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

who is at risk for aspergillus spp

A

Heme and HSCT patients- prolonged neutropenia

24
Q

What are other infections that attack neutropenic cancer patients

A

viruses
- HSV

Protozoan
- Pneumocystitis jirovecci (PJP)
- toxoplasma gondii
- TMP/SMX

25
How is toxoplasma gondii and PJP avoided
TMP/SMX prophylaxis
26
What is the most important finding in diagnosing infections in neutropenic cancer pts
Fever other s/s absent due to neutropenia
27
What are labs and diagnostics used in diagnosing infections in neutropenic cancer patients
Labs - blood culture - CBC with differential - BMP or CMP Diagnostics - imaging - aspiration or biopsy
28
For infection risk assessment of febrile neutropenia, what are low risk and high risk patients
low- neutropenia <7 days, clinically stable, inpatient or outpatient, IV and/or PO High- ANC <100 and neutropenia >7 days, clinically unstable, inpatient, IV therapy
29
What coverage should management of febrile neutropenia include
Antipseudomonal coverage
30
How to treat low risk febrile neutropenia (define low risk too)
Low risk- ANticipated neutropenia < 7 days, clinically stable and no medical comorbidities and outpatient at fever onset MASCC score > or = 21 If they meet criteria for outpatient Oral FQ + amox/clav If they do NOT meet criteria for outpatient use IV therapy piperacillin/tazobactam, cefepime, ceftazidine
31
how to treat high risk febrile neutropenia
Inpatient IV antibiotics - piperacillin tazobactam, cefepime, ceftazidime Add IV vancomycin for cellulitis, pneumonia, severe sepsis or shock or MRSA
32
Empiric therapy of febrile neutropenia
B lactam monotherapy - Cefepime or piperacillin/tazo are most common imipenem, Meropenem and ceftazidime may be used aswell
33
mono vs combination for management of febrile neutropenia
Comparable efficacy to combination regimens. Mono is better.
34
disadvantage of ceftazidime use in febrile neutropenia
No gram positive coverage so it might lead to selection of resistant organisms.
35
Is vancomycin recommended in initial empiric regimen for febrile neutropenia
NOT recommended as initial therapy
36
criteria for vanc addition for febrile neutropenia
- hemodynamically unstable (septic shock) - pneumonia - blood cultures frowing gram positive bacteria - Line/port infection - SSTI -Severe mucositis - Colonization with resistant gram positive bacteria
37
what do we do for penicillin allergy patients for febrile neutropenia
Avoid B lactams Use combo of cipro +aztreonam + vanc
38
oral regimens to give to outpatients low risk febrile neutropenia
cipro + amox clav (most common) levofloxacin ciprofloxacin + clindamycin
39
Compare efficacy oral antibiotics to IV for low risk febrile neutropenia. WHat are requirements to be on oral antibiotic therapy
comparable efficacy to IV Not to be used in pts already on FQ prophylaxis. Requires patient compliance and 24 hr access to medical care if instability develops
40
Targeted therapy for febrile neutropenia for MRSA, VRE, ESBL, KPC, NDM/IMP/VIM
MRSA- Vancomycin VRE- daptomycin or linezolid Extended spectrum beta lactamases- Carbapenem KPC (carbapenem resistant) (a- meropenem/vabrobactam, imipenem/cilastatin/relebactam, ceftazidime/avibactam NDM/IMP/VIM- cefiderocol
41
1. What to do for febrile neutropenia if low risk patient in outpatient continues to have fever? What to do if they are responding? Not responsing? 2. What to do for febrile neutropenia patient (high or low risk) that defervesced and are clinically stable?
1. admit to hospital and place on IV. If they respond treat 7-14 days as indicated by type/site of infection and until ANC>500 and rising If not reponding, modify/broaden by adding vancomycin and/or additional gram negative coverage. Consider antifungal. 2. Continue oral or IV antibiotics until ANC>500 and rising
42
WHen do we consider adding fungal therapy for management of febrile neutropenia
Patients with persistent fever or develop new fever with undocumented infection after 4-7 days. We can only isolate fungal infection from a person with fungus <50% of the time
43
What are treatment options for fungal treatment of febrile neutropenia? Duration?
Amphotericin B deoxycholate or liposomal amphotericin B Azoles (flucanozole, voriconazole, posaconazole, isavuconazole) Echinocandins (micafungin, caspofungin, anidulafungin Continue therapy for 2 wks in absence of s/s of fungal infenction
44
When do we use antiviral therapy for management of febrile neutropenia? What drugs to use
Vesicular/ulcerative skin or mucosal lesions, evaluate for HSV. Initiate Acyclovir, valacyclovir in HSV and ganciclovir/valganciclovir in CMV
45
most common pathogens seen in catheter related blood stream infections? What are indications for catheter removal?
S. aureus and S. epidermis are most common Indications - SQ tunnel infection - Failure to clear blood cultures after 72 hrs of sppropriate microbial therapy - persistent fever - Septic emboli
46
Wat are pathogens that we need to remove catheter for?
Fungi Mycobacteria P. aeruginosa Bacillus spp C. jeikeium
47
What is the most important determinant of patient outcomes for management of febrile neutropenia
Resulotion of neutropenia (faster we get them not to be neutropeniz the better outcome will be)
48
When do we use CSF? Name the drugs
May be useful in pts with ANC<500, uncontrolled primary disease, PNA, IFI (invasive fungal infection), hypotension, sepsis, multiorgan dysfunction with prolonged neutropenia who are NOT REPOSNDING to antimicrobial therapy
49
Advantage/disadvantage of CSF in pts
-decreased duration/severity of neutropenia - decreased duration of antimicrobial therapy - decreased hospitalization and reduced hospitalization stay but No benefit in mortality
50
WHat are two big aspects of prophylaxis for febrile neutropenia pts
Infection control (IC)- laminar flow rooms Patient population (who gets prophylaxis)- Moderate-high risk pts with expected ANC<100 for >7 days, Heme malignancy patients (AML, MM, Lymphoma, CLL), stem cell transplant pts, GVHD with high dose steroids, use of alemtuzumab
51
What to use as prophylaxis for febrile neutropenia pts
fluoroqinalone prophylaxis (Cipro or levo)
52
If we have breakthrough infection of fluoroquinalone prophylaxis, do we use FQ in empiric therapy?
no
53
When to use antifungal prophylaxis
Allogenic HSCT Intensive induction chemo for acute leukemia Azoles Echinocandina AML, MDS, GVHD on high dose steroids
54
When to use antiviral prophylaxis for febrile neutropenia pts
Annual inactivated influenza vaccine recommended for all pts HSV seropositive pts undergoing allogenic HSCT or leukemia induction therapy Varicella vaccine may be useful in seronegative adults
55
When to use TMP SMX as prophylaxis in febrile neutropenia pts
Allogenic HSCT and GVHD on high dose steroids Substantially reduces risk of PJP pneumonia
56

Therapeutics P3 Spring (31 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions